Emerging BTK inhibitors are positioned to change the landscape and impact your chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) treatment plans. Are you ready to incorporate these emerging therapies into your treatment plans? Dr. Sameer Parikh discusses these emerging BTK inhibitors for CLL/SLL, how they differ from current approaches, and future opportunities to introduce these therapies into your clinical decisions. Hear a patient case and the question and answer portion from this visiting lecture series. This activity also includes downloadable slides from the series to improve care for your patients with CLL/SLL.

To claim credit: https://www.achlcme.org/btk-inhibitors-cll-sll-onctube

Dive into additional groundbreaking treatment approaches for triple-negative breast cancer (TNBC) in this tumor board, the second in a series focused on TNBC. This multidisciplinary tumor board discusses a patient with advanced TNBC and how novel anti-TROP2 antibody-drug conjugates (ADCs) therapy may play a role.

Claim credit: https://www.achlcme.org/tnbc-case-challenge-onctube

Access the three-part series: https://www.achlcme.org/triple-negative-breast-cancer

Explore the latest groundbreaking treatment approaches for early-stage triple-negative breast cancer (TNBC) in this engaging tumor board!  The multidisciplinary panel of expert faculty will dive into a case involving a patient with early TNBC and discuss the latest data and potential roles of PARP inhibitors (PARPIs) in the first CME activity offered in this TNBC series.

Claim credit: https://www.achlcme.org/PARPis-tnbc-onctube

Access the three-part series: https://www.achlcme.org/triple-negative-breast-cancer

Can you make optimal treatment choices for challenging triple-negative breast cancer (TNBC) cases? Put your TNBC skills to the test in these interactive case challenges. As the third and final activity in the TNBC series, you will navigate through two cases. Education is built into the cases, on practical strategies to meet the treatment needs of diverse patients with TNBC.

Access the full case study: https://www.achlcme.org/tnbc-case-challenge-onctube

View the three-part series: https://www.achlcme.org/triple-negative-breast-cancer

With over 55% of cancer patients treated by community oncologists, it’s imperative that community oncologists and pathologists apply a multidisciplinary team approach to caring for patients. As precision medicine continues to evolve in cancer care, the integration of pathologists within clinical care pathways to interpret test results and offer recommendations for biomarker testing aid in personalized treatment approaches.

This series offers two interactive programs supported by audio and video commentary, where expert faculty share insights on molecular testing recommendations, guidance on interpreting molecular testing results, and clinical trial evidence in order to help clinicians:
• Increase implementation of best practices for EGFR mutation testing in patients with NSCLC
• Apply clinical trial data to treatment selection in patients with EGFR-mutant NSCLC
• Understand the role of concurrent mutations, such as TP53, in the prognosis and response to therapy of patients with EGFR-mutant NSCLC

Access the interactive infographic, case study, and claim credit: https://www.achlcme.org/egfr-mutation-testing-onctube

Prophylactic management of hemophilia continues to be a challenge. This nurse-led activity discusses treatment strategies, safety and efficacy of current available products, and how to improve patient adherence.  In this clinical commentary, expert faculty, Kerry H. Hansen, RN, BS and Skye Peltier, MPH, PA-C review best practices to facilitate successful therapeutic interventions with hemophilia A prophylaxis.

Claim credit: https://www.achlcme.org/hemophilia-a-prophylaxis-onctube

This immersive practice guide offers “how to” methods and day-to-day strategies via faculty commentary and a review of data and guideline recommendations. Expert faculty address which approaches may not be working, complexities in managing this patient population, insights on how the latest evidence supports a practical recommendation and review available therapies to optimize treatment selection.

Claim credit: https://www.achlcme.org/multiple-myeloma-onctube

Despite the advances in precision medicine for non-small cell lung cancer (NSCLC), a significant proportion of patients, particularly African American and Hispanic patients, face inequities with access to these health breakthroughs. In this activity, expert faculty focus on the latest evidence with NSCLC disparities of care and how to best overcome these barriers. The activity also reviews how to assess opportunities to increase referral of minority patients to clinical trials and how to optimize overall care coordination among minority patients with NSCLC.

Claim credit: https://www.achlcme.org/reduce-health-disparities-nsclc-onctube

Are you aware that Black men continue to suffer worse outcomes compared to White men with prostate cancer? Through this education, learners improve their ability to recognize systemic, behavioral and sociocultural factors creating disparate health outcomes in prostate cancer, improve identification of patients at risk, and expedite time to diagnosis and time to treatment.

Access the toolkit: https://www.prostatecancerdisparities.org/

Claim credit: https://www.achlcme.org/reduce-prostate-cancer-disparities-onctube

In this panel discussion and workshop, experts from the University of Chicago Medicine and the University of Illinois Cancer Center discuss structural racism and disparities faced by women receiving breast cancer care. Discussion is centered around strategies to address these disparities. The experts are also joined by patient advocates sharing their personal experiences and how providers can provide support.

This activity was included in a series of workshops as part of a quality improvement program “Leading the Way: Improving Breast Cancer Disparities for Minority Patients in Chicago.” Led by Olufunmilayo Olopade, MD, FACP, this initiative is studying the effectiveness of targeted interventions in improving breast cancer care for African American women treated in Cook County.

To learn more visit: fightingBCdisparities.com

To claim credit: https://www.achlcme.org/breast-cancer-equity

In this workshop, Dr. Nan Chen from the University of Chicago Medicine discusses the oncology, surgical, and radiation treatment experiences of white and Black women. Dr. Chen also reviews barriers, common misconceptions with breast cancer treatment, and interventions clinicians can employ to overcome racial disparities in breast cancer.

This activity was included in a series of workshops as part of a quality improvement program “Leading the Way: Improving Breast Cancer Disparities for Minority Patients in Chicago.” Led by Olufunmilayo Olopade, MD, FACP, this initiative is studying the effectiveness of targeted interventions in improving breast cancer care for African American women treated in Cook County.

Learn more at fightingBCdisparities.com

Claim credit: https://www.achlcme.org/breast-cancer-treatment

In this workshop, Dr. Nan Chen from the University of Chicago Medicine discusses screening and mammography rates among racial/ethnic groups. Dr. Chen also touches on the impact of the COVID-19 pandemic, factors that influence disparities such as fears and misperceptions, the underutilization of genetic counseling and testing, and the importance of patient communication and navigation.

Learn how you can address disparities in your own patient care. This activity was included in a series of workshops as part of a quality improvement program “Leading the Way: Improving Breast Cancer Disparities for Minority Patients in Chicago.” Led by Olufunmilayo Olopade, MD, FACP, this initiative is studying the effectiveness of targeted interventions in improving breast cancer care for African American women treated in Cook County.

Learn more: fightingBCdisparities.com

Claim credit: https://www.achlcme.org/breast-cancer-screening-diagnosis